doi:10.3969/j.issn.1004-583X.2024.01.016

Abstract

CLC Number:

R575.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.01.016

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I1/84

References 38

[1]	Montano-Loza AJ, Allegretti JR, Cheung A, et al. Single topic conference on autoimmune liver disease from the Canadian Association for the study of the liver[J]. Can Liver J, 2021, 4(4): 401-425. doi: 10.3138/canlivj-2021-0006 URL
[2]	The Committee of the Autoantibodies Detection of Rheumatology and Immunology Physicians Committee of Chinese Medical Doctor Association. Expert consensus on clinical application of autoantibodies detection in patients with autoimmune liver disease[J]. Chin J Intern Med, 2021, 60(7): 619-625.
[3]	中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 中华肝脏病杂志, 2022, 30(3): 264-275.
[4]	Schulz L, Sebode M, Weidemann SA, et al. Variant syndromes of primary biliary cholangitis[J]. Best Pract Res Clin Gastroenterol, 2018, 34-35:55-61. doi: S1521-6918(18)30027-1 pmid: 30343711
[5]	Li Z, Liu Y, Yang F, et al. Dysregulation of circulating FGF19 and bile acids in primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Biomed Res Int, 2020, 2020:1934541.
[6]	To U, Silveira M. Overlap syndrome of autoimmune hepatitis and primary biliary cholangitis[J]. Clin Liver Dis, 2018, 22(3): 603-611. doi: S1089-3261(18)30035-7 pmid: 30259856
[7]	Yan YL, Xing X, Wang Y, et al. Clinical utility of two-dimensional shear-wave elastography in monitoring disease course in autoimmune hepatitis-primary biliary cholangitis overlap syndrome[J]. World J Gastroenterol, 2022, 28(18): 2021-2033. doi: 10.3748/wjg.v28.i18.2021 URL
[8]	European Association for the Study of the Liver. EASL clinical practice guidelines: The diagnosis and management of patients with primary biliary cholangitis[J]. J Hepatol, 2017, 67(1): 145-172. doi: S0168-8278(17)30186-1 pmid: 28427765
[9]	Chazouillères O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy[J]. Hepatology, 1998, 28(2):296-301. doi: 10.1002/hep.510280203 pmid: 9695990
[10]	倪萍, 凡小丽, 杨丽. 自身免疫性肝病重叠综合征的研究现状[J]. 临床肝胆病杂志, 2020, 36(4): 743-748.
[11]	Kuiper EM, Zondervan PE, Van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome[J]. Clin Gastroenterol Hepatol, 2010, 8(6): 530-534. doi: 10.1016/j.cgh.2010.03.004 URL
[12]	Liu F, Pan ZG, Ye J, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Simplified criteria may be effective in the diagnosis in Chinese patients[J]. J Dig Dis, 2014, 15(12): 660-668. doi: 10.1111/cdd.2014.15.issue-12 URL
[13]	张骏飞, 许何明, 宋海燕, 等. 自身免疫性肝炎-原发性胆汁性胆管炎重叠综合征:巴黎标准诊断中国患者灵敏度低[J]. 实用肝脏病杂志, 2019, 22(4): 537-540.
[14]	杨宁, 刘雁声, 韩英. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治[J]. 临床肝胆病杂志, 2020, 36(3): 697-700.
[15]	Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue[J]. J Hepatol, 2011, 54(2): 374-385. doi: 10.1016/j.jhep.2010.09.002 pmid: 21067838
[16]	Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5):929-538. doi: 10.1016/s0168-8278(99)80297-9 pmid: 10580593
[17]	Hennes EM, Zeniya M, Czaja AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. doi: 10.1002/hep.22322 pmid: 18537184
[18]	Neuhauser M, Bjornsson E, Treeprasertsuk S, et al. Autoimmune hepatitis-PBC overlap syndrome: A simplified scoring system may assist in the diagnosis[J]. Am J Gastroenterol, 2010, 105(2): 345-353. doi: 10.1038/ajg.2009.616 pmid: 19888204
[19]	Zhang W, De D, Mohammed KA, et al. New scoring classification for primary biliary cholangitis-autoimmune hepatitis overlap syndrome[J]. Hepatol Commun, 2018, 2(3): 245-253. doi: 10.1002/hep4.1148 pmid: 29507900
[20]	Harms MH, van Buuren HR, Corpechot C, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis[J]. J Hepatol, 2019, 71(2): 357-365. doi: S0168-8278(19)30228-4 pmid: 30980847
[21]	Gordon SC, Wu KH, Lindor K, et al. Ursodeoxycholic acid treatment preferentially improves overall survival among African Americans with primary biliary cholangitis[J]. Am J Gastroenterol, 2020, 115(2): 262-270. doi: 10.14309/ajg.0000000000000512 pmid: 31985529
[22]	中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 中华肝脏病杂志, 2022, 30(5): 482-492.
[23]	Chen RL, Wang QX, Ma X. Precision medicine for autoimmune hepatitis[J]. J Dig Dis, 2019, 20(7): 331-337. doi: 10.1111/cdd.2019.20.issue-7 URL
[24]	王绮夏, 马雄. 自身免疫性肝病重叠综合征诊治进展[J]. 胃肠病学, 2018, 23(5): 283-286.
[25]	张晓梅. 熊去氧胆酸单药治疗原发性胆汁性肝硬化肝炎重叠综合征的临床研究[J]. 现代消化及介入诊疗, 2017, 22(4): 487-489.
[26]	郭丽萍, 周璐, 李树倩, 等. 熊去氧胆酸单药或联合免疫抑制剂治疗原发性胆汁性肝硬化-自身免疫性肝炎重叠综合征的疗效分析[J]. 中华消化杂志, 2016, 36(3): 155-160.
[27]	Chazouillères O, Wendum D, Serfaty L, et al. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome[J]. J Hepatol, 2006, 44(2): 400-406. doi: 10.1016/j.jhep.2005.10.017 pmid: 16356577
[28]	Ozaslan E, Efe C, Heurgué-Berlot A, et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2014, 12(5): 863-869. doi: 10.1016/j.cgh.2013.09.021 URL
[29]	Fan X, Zhu Y, Men R, et al. Efficacy and safety of immunosuppressive therapy for PBC-AIH overlap syndrome accompanied by decompensated cirrhosis: A real-world study[J]. Can J Gastroenterol Hepatol, 2018, 2018: 1965492.
[30]	Freedman BL, Danford CJ, Patwardhan V, et al. Treatment of overlap syndromes in autoimmune liver disease: A systematic review and meta-analysis[J]. J Clin Med, 2020, 9(5): 1449.
[31]	Baven-Pronk AM, Coenraad MJ, Van Buuren HR, et al. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes[J]. Aliment Pharmacol Ther, 2011, 34(3): 335-343. doi: 10.1111/apt.2011.34.issue-3 URL
[32]	Efe C, Hagström H, Ytting H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2017, 15(12): 1950-1956. doi: 10.1016/j.cgh.2017.06.001 URL
[33]	Hanouneh M, Ritchie MM, Ascha M, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis[J]. Scand J Gastroenterol, 2019, 54(1): 76-80. doi: 10.1080/00365521.2018.1551498 URL
[34]	Faisal N, Renner EL. Recurrence of autoimmune liver diseases after liver transplantation[J]. World J Hepatol, 2015, 7(29): 2896-2905. doi: 10.4254/wjh.v7.i29.2896 pmid: 26689244
[35]	Liberal R, Zen Y, Mieli-Vergani G, et al. Liver transplantation and autoimmune liver diseases[J]. Liver Transpl, 2013, 19(10): 1065-1077. doi: 10.1002/lt.v19.10 URL
[36]	Silveira MG, Talwalkar JA, Angulo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: Long-term outcomes[J]. Am J Gastroenterol, 2007, 102(6): 1244-1250. pmid: 17319931
[37]	Park Y, Cho Y, Cho EJ, et al. Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: Characteristics, treatments, and outcomes[J]. Clin Mol Hepatol, 2015, 21(2): 150-157. doi: 10.3350/cmh.2015.21.2.150 pmid: 26157752
[38]	Yang F, Wang Q, Wang Z, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis[J]. Clin Rev Allergy Immunol, 2016, 50(1): 114-123. doi: 10.1007/s12016-015-8516-5 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 38

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(2): 177-182.
[2]	Yang Zhibin, Shao Yanfang, Pan Li, Yang Yanxia, Yang Yuxi, Zhao Lihui, Zeng Rongkun, Li Yang, Wang Qiaofeng, Wang Cong, Ma Shiwu. Efficacy of magnesium isoglycyrrhizinate in anti-tuberculosis drug-induced liver injury [J]. Clinical Focus, 2021, 36(11): 972-975.
[3]	. [J]. Clinical Focus, 2021, 36(9): 856-860.
[4]	. [J]. Clinical Focus, 2021, 36(6): 574-576.
[5]	. [J]. CLINICAL FOCUS, 2014, 29(2): 202-203.
[6]	. [J]. CLINICAL FOCUS, 2013, 28(7): 812-813.
[7]	WANG Pu;LIU Jiang-wen;TONG De-feng;CUI Yong. Effects of 15-deoxy-prostaglandin J2 on expression of proliferator-activated receptor γ,tumor necrosis factor-α and interleukin-6 in liver tissue of rats with nonalcoholic fatty liver disease [J]. Clinical Focus, 2013, 28(4): 412-0.
[8]	. [J]. Clinical Focus, 2012, 27(22): 1993-1994.
[9]	. [J]. Clinical Focus, 2012, 27(18): 1610-1611.
[10]	ZHANG Jun-xia;LIU Jun-juan;LI Jia. Clinical characteristics of 42 autoimmune hepatitis patients [J]. Clinical Focus, 2012, 27(12): 1050-1053.
[11]	. [J]. Clinical Focus, 2011, 26(24): 2170-2171.
[12]	. [J]. CLINICAL FOCUS, 2011, 26(20): 1811-1813.
[13]	ZHAO Zhao-xia;YE Li-hong;LU Jian-hua;YANG Li;LIU Yan-chao;LIU Yu-zhen;HOU Jun-liang;DAI Er-hei . Quantification of liver hepatitis B virus covalently closed circular DNA in patients with chronic hepatitia B [J]. CLINICAL FOCUS, 2011, 26(13): 1108-1110.
[14]	. [J]. CLINICAL FOCUS, 2010, 25(24): 2174-2174.
[15]	. [J]. CLINICAL FOCUS, 2010, 25(23): 2106-2108.